LCM
Laurion Capital Management Portfolio holdings
AUM
$867M
1-Year Return
5.19%
This Quarter Return
+3.22%
1 Year Return
+5.19%
3 Year Return
+14.26%
5 Year Return
+18.43%
10 Year Return
+26.97%
AUM
$3.6B
AUM Growth
+$807M
(+29%)
Cap. Flow
+$734M
Cap. Flow
% of AUM
20.42%
Top 10 Holdings %
Top 10 Hldgs %
28.81%
Holding
467
New
156
Increased
40
Reduced
28
Closed
91
Top Buys
| 1 |
Apple
AAPL
|
$109M |
| 2 |
CVS Health
CVS
|
$96M |
| 3 |
Adobe
ADBE
|
$90.1M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
$70.7M |
| 5 |
Microsoft
MSFT
|
$69.4M |
Top Sells
| 1 |
Kenvue
KVUE
|
$156M |
| 2 |
Vistra
VST
|
$144M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$121M |
| 4 |
General Motors
GM
|
$85M |
| 5 |
Honeywell
HON
|
$72.5M |
Sector Composition
| 1 | Healthcare | 38.37% |
| 2 | Technology | 18.29% |
| 3 | Consumer Discretionary | 9.42% |
| 4 | Financials | 7.94% |
| 5 | Energy | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Nucor
NUE
$33.8B
| $4.76M | 0.04% |
+24,077
| New | +$4.76M |
|
127
Abeona Therapeutics
ABEO
$353M
| $4.69M | 0.04% |
+646,830
| New | +$4.69M |
|
128
Lyra Therapeutics
LYRA
$11.3M
| $4.65M | 0.04% |
14,957
+14,109
| +1,664% | +$4.39M |
|
|
HCP
129
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $4.6M | 0.04% |
+170,591
| New | +$4.6M |
|
|
ELEV
130
DELISTED
Elevation Oncology
ELEV
| $4.56M | 0.04% |
+888,889
| New | +$4.56M |
|
131
Black Diamond Therapeutics
BDTX
$167M
| $4.45M | 0.04% |
+878,286
| New | +$4.45M |
|
132
C4 Therapeutics
CCCC
$194M
| $4.37M | 0.04% |
+535,342
| New | +$4.37M |
|
|
DCPH
133
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $4.32M | 0.04% |
+274,634
| New | +$4.32M |
|
134
International Flavors & Fragrances
IFF
$16.9B
| $4.3M | 0.04% |
+50,000
| New | +$4.3M |
|
|
CMPS
135
Compass Pathways
CMPS
$493M
| $4.25M | 0.04% |
510,907
| – | – |
|
136
Tyler Technologies
TYL
$24.2B
| $4.15M | 0.04% |
+9,771
| New | +$4.15M |
|
137
American Superconductor
AMSC
$2.21B
| $4.06M | 0.03% |
300,323
| – | – |
|
138
Atossa Therapeutics
ATOS
$102M
| $4.01M | 0.03% |
2,225,800
| – | – |
|
139
UroGen Pharma
URGN
$873M
| $3.76M | 0.03% |
250,600
| – | – |
|
140
Bio-Techne
TECH
$8.46B
| $3.75M | 0.03% |
+53,317
| New | +$3.75M |
|
141
The RealReal
REAL
$999M
| $3.7M | 0.03% |
945,614
| – | – |
|
142
Tarsus Pharmaceuticals
TARS
$2.43B
| $3.64M | 0.03% |
+100,000
| New | +$3.64M |
|
143
United Parcel Service
UPS
$72.1B
| $3.49M | 0.03% |
+23,478
| New | +$3.49M |
|
144
Immunocore
IMCR
$1.87B
| $3.47M | 0.03% |
+53,332
| New | +$3.47M |
|
145
Corpay
CPAY
$22.4B
| $3.38M | 0.03% |
+10,949
| New | +$3.38M |
|
146
ADT
ADT
$7.13B
| $3.36M | 0.03% |
+500,000
| New | +$3.36M |
|
147
Ultragenyx Pharmaceutical
RARE
$3.07B
| $3.17M | 0.03% |
+68,000
| New | +$3.17M |
|
|
BBOT
148
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$784M
| $3.11M | 0.03% |
+300,000
| New | +$3.11M |
|
|
INZY
149
DELISTED
Inozyme Pharma
INZY
| $3.08M | 0.03% |
402,197
-155,132
| -28% | -$1.19M |
|
150
LifeMD
LFMD
$287M
| $2.94M | 0.02% |
285,637
| – | – |
|